Using body composition to predict treatment-related adverse events and disease-free survival in patients with gastrointestinal stromal tumors treated with imatinib: a retrospective cohort study
Baseline body composition parameters, particularly myosteatosis, effectively predict the adverse events and DFS in patients taking imatinib. Personalized treatment, such as targeted nutritional and exercise interventions, and close monitoring of patients with myosteatosis or sarcopenia can enhance compliance and improve survival rates.
Authors
- Tengyun Li
- Tianhao Gu (ORCID: https://orcid.org/0000-0002-8635-8577)
- Hao Xu (ORCID: https://orcid.org/0000-0001-5827-1821)
- Jun Xu (ORCID: https://orcid.org/0000-0001-7255-9952)
- Qianzheng Zhou
- Zekuan Xu (ORCID: https://orcid.org/0000-0001-5179-4128)
- Qiong Li (ORCID: https://orcid.org/0009-0006-5872-2446)
- Jianan Zhang (ORCID: https://orcid.org/0000-0001-9801-2779)
- Dinghua Yang (ORCID: https://orcid.org/0000-0002-1442-5240)
- Fengyuan Li (ORCID: https://orcid.org/0009-0002-1217-4000)
Institutions
- Jiangsu Province Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.3389/fimmu.2025.1576834
- Primary Topic
- Gastrointestinal Tumor Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00